A nurse prescriber-led protocol for anaemia management in established haemodialysis patients: A retrospective study.

AIM AND OBJECTIVE: To evaluate the impact of a nurse prescriber-led protocol compared to a traditional physician-led nonprotocol-based approach had on maintaining targeted haemoglobin levels in patients on maintenance haemodialysis. BACKGROUND: Anaemia is a common complication of chronic kidney disease and has a profound impact on the patients' well-being. Current practices place a greater emphasis on the decision-making role of nurses in renal anaemia management. The introduction of nurse prescribing in this area is a relatively new concept. DESIGN: A retrospective cohort design, covering an eight-month period pre- and post introduction of a nurse prescriber-led anaemia protocol; study adheres to the STROBE Statement. METHODS: Using a nonprobability convenience sample, data extracted from the medical records and electronic patient records system (eMed) related to 74 patients at a single outpatient haemodialysis centre located within an acute general teaching hospital. The primary outcome was patients' haemoglobin level pre- and post introduction of the protocol. Secondary outcomes included erythropoietin-stimulating agent and iron dosage, and serum ferritin and transferrin saturation levels. RESULTS: There were no statistically significant differences between pre- and post protocol serum haemoglobin level and erythropoietin-stimulating agent dosage. Under the management of the nurse prescriber, patients experienced a significant improvement in serum ferritin and transferrin saturation levels and required significantly less intravenous iron dosage. CONCLUSIONS: This study, the first of its kind, found that patients receiving haemodialysis experience a significant improvement in iron indices while receiving a significantly lower amount of intravenous iron when managed by a nurse prescriber. Furthermore, the nurse prescribers' decision-making capacity is as effective as a physician-led nonprotocol-based approach in achieving haemoglobin target levels. RELEVANCE TO CLINICAL PRACTICE: Nurse prescribers have a role in implementing a safe, standardised and sustained approach to anaemia management in outpatient haemodialysis settings without compromising patient care.

Evaluating the Effectiveness of an Educational Intervention for Care of Anemic Patients in a Long-Term Care Geropsychiatric Unit: A Pilot Study.

Anemia is one of the most common age-related health conditions. When concurrently present with psychiatric conditions, the problem is confounded. The primary objective of the current research was to evaluate the effectiveness of an educational intervention for geropsychiatric nurses about nutritional deficiency anemia, anemia of chronic disease, and unexplained anemia in older adults. Fifty nurses employed by an inpatient psychiatric facility participated in the pilot study. A 10-item knowledge evaluation questionnaire was administered prior to and following a 45-minute educational intervention. Analysis of a paired samples t test indicated a significant difference between pretest scores (mean = 36.8, SD = 16.3) and posttest scores (mean = 90.8, SD = 10.66) (p < 0.001). Despite initial knowledge gaps, significant improvement in nursing knowledge was noted following the intervention. As a result of improved knowledge, RNs may be better able to recognize and respond to signs and symptoms that commonly go unnoticed in geropsychiatric patients with anemia. [Journal of Gerontological Nursing, 46(8), 12-16.].

Implementation of a Nurse-Empowered Renal Anemia Protocol in Children.

A high proportion of patients on hemodialysis persist with low hemoglobin levels despite receiving treatment with erythropoiesis-stimulating agents. A registered nurse-driven renal anemia protocol was designed and implemented by a team in a pediatric hemodialysis unit. We compared proportion of patients achieving the target hemoglobin (Hgb) and transferrin saturation (TSAT) before and after the implementation of the protocol. There was an increase in patients achieving the target Hgb and TSAT range, with an increase in the Hgb concentration. There were no differences in the proportion of patients with left ventricular hypertrophy, erythropoiesis-stimulating agents or intravenous iron dose, transfusion rates, or hospitalization rates. The implementation of a nurse-driven anemia protocol in a pediatric hemodialysis unit increased the proportion of patients achieving target Hgb and TSAT range without a rise in medication doses.

Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes.

AIMS AND OBJECTIVES: To determine whether the use of a nurse-driven protocol in the haemodialysis setting is as safe and effective as traditional physician-driven approaches to anaemia management. BACKGROUND: The role of haemodialysis nurses in renal anaemia management has evolved through the implementation of nurse-driven protocols, addressing the trend of exceeding haemoglobin targets and rising costs of erythropoietin-stimulating agents. DESIGN: Retrospective, non-equivalent case control group design. METHODS: The sample was from three haemodialysis units in a control group (n = 64) and three haemodialysis units in a protocol group (n = 43). The protocol group used a nurse-driven renal anaemia management protocol, while the control group used a traditional physician-driven approach to renal anaemia management. All retrospective data were obtained from a provincial renal database. Data were analysed using chi-square tests and t-tests. Patient outcomes examined were haemoglobin levels, transferrin saturation levels, erythropoietin-stimulating agents use and intravenous iron use. Cost comparisons were determined using average use of erythropoietin-stimulating agents and intravenous iron. RESULTS: Control and protocol groups reached haemoglobin target levels. In the protocol group, 75% reached transferrin saturation target levels in comparison with 25% of the control group. Use and costs for iron was higher in the control group, while use and costs for erythropoietin was higher in the protocol group. The higher usage of erythropoietin-stimulating agents was potentially related to comorbid conditions amongst the protocol group. CONCLUSIONS: A nurse-driven protocol approach to renal anaemia management was as effective as the physician-driven approach in reaching haemoglobin and transferrin saturation levels. Further examination of the use and dosing of erythropoietin-stimulating agents and intravenous iron, their impact on haemoglobin levels related to patient comorbidities and subsequent cost effectiveness of protocols is required. RELEVANCE TO CLINICAL PRACTICE: Using a nurse-driven protocol in practice supports the independent nursing role while contributing to safe patient outcomes.

Postpartum anaemia. Are we vigilant enough?

Anaemia in the immediate postnatal period can manifest itself physically in a number of ways. Amongst these are pallor, tiredness, dizziness, loss of appetite and oedema (Bewley 2004), all of which could be mistaken for commonly observed benign symptoms of the immediate postnatal period. However, left untreated, anaemia can severely impact on both the physical and emotional wellbeing of a woman and dramatically slow down her recovery (Bewley 2004). This altered state of health can also have a detrimental effect on a woman's ability to bond with her new child (Abbott et al 1997) and has been identified as a contributory factor in the initiation of postnatal depression (Corwin et al 2003). It is therefore imperative that, as midwives and student midwives, we take every opportunity to closely monitor the wellbeing of women in our care in order to facilitate their return to a normal haemoglobin level, promote infant bonding and reduce the risk of postnatal depression.

Anemia management: a story of sleuthing.

ESA therapy is commonly initiated when the Hgb is less than 11 g/dL. The shared hope and expectation as we partner with patients and their families in the plan of care is that the way to attain intended outcomes will be clear and involve no mystery. It can be surprising and challenging when those outcomes are not easily met. Mr. I achieved the targets for TSAS and ferritin levels, and both he and his significant other demonstrated knowledge about anemia and its ramifications and skill in the administration of the ESA. However, during the time he was enrolled in the CKD anemia management program, he did not achieve or maintain a Hgb between 11.0 and 12.0 g/dL. What are the lessons learned and implications for nephrology nurses? Be specific with patients about their medications. Ask about injectable and intravenous medications, radiotherapy, drugs that affect DNA synthesis (such as chemotherapeutic drugs), street drugs, herbal therapies, and vitamins. Be thorough when obtaining a medical and lifestyle history, especially as it relates to conditions that may affect erythropoiesis, for example, is the patient smoking? How much alcohol does he drink? Has he seen a Healthcare provider for any old or new problems recently? In addition, patients with CKD have many co-morbidities, which may include cancer. ESA therapy becomes much more complex in the patient with cancer and CKD, and therapy may necessitate a different approach and different Hgb targets. Finally, nurses must be diligent and methodical in the quest to uncover the reasons for hyporesponsiveness in the patient with CKD who has anemia.

Pathophysiology of anemia and nursing care implications.

Anemia is a decrease in erythrocyte mass or amount of hemoglobin from impaired production of erythrocytes, blood loss, or increased erythocyte destruction. The pathophysiology, clinical manifestations, and selected pathologies of anemia and their implications for nursing practice are reviewed.

Chronic kidney disease anaemia. 2: Overview of guidance.

This is part 2 of a two-part unit on managing anaemia of chronic kidney disease (CKD). Part 1 outlined its prevalence, causes, signs and symptoms, and screening for it. Part 2 presents key points from published guidance and a summary of treatment options, and discusses nurses' role in managing people who have anaemia in CKD.

Controlling Phlebotomy Volume Diminishes PICU Transfusion: Implementation Processes and Impact.

BACKGROUND AND OBJECTIVES: Phlebotomy excess contributes to anemia in PICU patients and increases the likelihood of red blood cell transfusion, which is associated with risk of adverse outcomes. Excessive phlebotomy reduction (EPR) strategies may reduce the need for transfusion, but have not been evaluated in a PICU population. We hypothesized that EPR strategies, facilitated by implementation science methods, would decrease excess blood drawn and reduce transfusion frequency. METHODS: Quantitative and qualitative methods were used. Patient and blood draw data were collected with survey and focus group data to evaluate knowledge and attitudes before and after EPR intervention. The Consolidated Framework for Implementation Research was used to interpret qualitative data. Multivariate regression was employed to adjust for potential confounders for blood overdraw volume and transfusion incidence. RESULTS: Populations were similar pre- and postintervention. EPR strategies decreased blood overdraw volumes 62% from 5.5 mL (interquartile range 1-23) preintervention to 2.1 mL (interquartile range 0-7.9 mL) postintervention (P < .001). Fewer patients received red blood cell transfusions postintervention (32.1% preintervention versus 20.7% postintervention, P = .04). Regression analyses showed that EPR strategies reduced blood overdraw volume (P < .001) and lowered transfusion frequency (P = .05). Postintervention surveys reflected a high degree of satisfaction (93%) with EPR strategies, and 97% agreed EPR was a priority postintervention. CONCLUSIONS: Implementation science methods aided in the selection of EPR strategies and enhanced acceptance which, in this cohort, reduced excessive overdraw volumes and transfusion frequency. Larger trials are needed to determine if this approach can be applied in broader PICU populations.

The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses.

The National Kidney Foundation Kidney Disease Outcomes Quality Initiative recently published revised clinical practice guidelines and recommendations for the treatment of anemia. This article provides an overview of the new guidelines and recommendations, with a focus on the hemoglobin treatment range, iron status, use of erythropoiesis-stimulating agents, and adjuvant therapies.

Optimising the management of anaemia in patients with cancer with practice guidelines using erythropoiesis-stimulating proteins.

Anaemia, a common problem in patients with cancer, usually leads to severe fatigue, which can dramatically impair patients' quality of life (QOL). Nurses are in the ideal position to assess and monitor cancer patients at risk of anaemia and recommend appropriate supportive care measures to alleviate anaemia-related symptoms. Erythropoiesis-stimulating proteins (ESPs) can increase haemoglobin levels, reduce the need for red blood cell transfusions, and improve QOL in patients with cancer and anaemia. Evidence-based guidelines published by national and international organisations make specific recommendations for the appropriate use of ESPs. Nurses are key members of the multidisciplinary teams that develop practice-specific protocols, which are based on the national guidelines. The practice guidelines should describe protocols to identify patients at risk for anaemia and interventions to correct anaemia, with specific details on the choice of ESP and when such interventions should be initiated and halted. In addition, nurses should also recommend strategies to reduce patient burden, such as patient self-administration with prefilled pens or synchronisation of visits for ESPs with chemotherapy visits, which is made possible with the once-every-3-weeks extended dosing with darbepoetin alfa. The implementation of such practice guidelines should improve the quality of care provided to patients.

Current practice in renal anaemia management: two multinational surveys.

The European Best Practice Guidelines recommend that 85% of patients with standard causes of chronic renal failure should achieve a target haemoglobin concentration of > or = 11 g/dL. However, patient outcomes need to be improved as many patients respond suboptimally to treatment and fail to reach these targets. Two multinational surveys of nursing practice in the management of renal anaemia in northern (with comparative data from Australia) and southern Europe were conducted. The aim was to assess variations in the role and amount of responsibility delegated to nurses in renal units throughout Europe and Australia. Patient care could be optimised by developing formal training and educational programmes for nephrology nurses and this has already occurred in many units in the UK.

Quality of life in patients on dialysis: benefits of maintaining a hemoglobin of 11 to 12 g/dL.

Clinical data have consistently demonstrated that improvements in quality of life (QOL) are associated with hemoglobin (Hb) and hematocrit (Hct) levels maintained in the range recommended by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Hb levels between 11 and 12 g/dL and Hct levels between 33% to 36% yield significant improvements in a wide variety of parameters in the physical, cognitive, and psychological/social domains.

Functional ability of patients on dialysis: the critical role of anemia.

Maintining hemoglobin (Hb) levels in the range (11 to 12 g/dL) recommended by the National Kidney Foundation's Kidney Disease Quality Initiative (NKF/KDOQI) has been shown to significantly improve functional ability in patients on dialysis. The combination of partial anemia correction and an individualized exercise program yields additional incremental benefits. Nurses fulfill a crucial role in ensuring that appropriate Hb levels are maintained while at the same time encouraging patients to improve their physical conditioning and functional status.

Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data.

Anemia is a common and serious complication of chronic kidney disease (CKD), which can be successfully and safely treated with erythropoiesis-stimulating proteins (ESPs). Darbepoetin alfa, a long-acting ESP, can be dosed less frequently than Epoetin alfa, thereby reducing the burden on patients and health care staff. This review summarizes recent clinical data supporting use of darbepoetin alfa at extended dosing intervals of once every 2 weeks and once monthly in patients with CKD not on dialysis.

Anemia management protocols: providing consistent hemoglobin outcomes.

Anemia management protocols encourage a consistent therapeutic approach that can increase the likelihood of patients achieving and maintaining stable hemoglobin levels within the target range of 17 to 12 g/dL recommended by the National Kidney Foundation. This article provides an overview of current concepts of anemia management that can be integrated into protocol development and refinement.